18 results about "Channel modulator" patented technology

Provided in the present invention are a compound as represented by formula I which can be used as a sodium channel modulator, and a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. Further provided are a pharmaceutical composition containing the compound and the stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, and a carrier or an excipient, and the pharmaceutical use thereof as an NaV1.8 inhibitor (against, for example, pain, respiratory diseases, neurological disorders, and mental diseases).

The present invention provides, inter alia, apelin receptor agonists having increased half-life, reduced desensitization, improved apelin receptor signaling properties (e.g., bias of G a signaling over arrestin signaling), enhanced stability, and / or enhanced binding to apelin receptors.

Fused heteroaryl compounds and compositions useful for preventing and / or treating a disease or condition related to aberrant function of voltage-gated sodium ion channels, e.g., an abnormal, delayed / persistent sodium current. Treatment methods for a disease or condition related to aberrant function of sodium ion channels are also provided herein, including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders.

Described herein, in part, are methods useful for preventing and / or treating a disease or condition relating to aberrant function or activity of a T-type calcium channel, such as psychiatric disorders (e.g., mood disorder (e.g., major depressive disorder)), pain, tremor (e.g., essential tremor), seizures (e.g., absence seizures), epilepsy, or an epilepsy syndrome (e.g., juvenile myoclonic epilepsy). The present invention further comprises methods for modulating the function of a T-type calcium channel and methods of administering a titrated dosage of a T-type calcium channel antagonist.

Disclosed herein are compounds of formulae (I), (II), and (III) and a pharmaceutically acceptable salts thereof. Also disclosed herein are uses of compounds of formulae (I), (II), and (III), as well as pharmaceutically acceptable salts thereof in the potential treatment or prevention of a disease or disorder which is modulated by the Kv3 potassium channels in a subject in need thereof. Also disclosed are compositions comprising one or more of the compounds. Further disclosed herein are uses of these compositions in the potential prevention or treatment of a disease or disorder which is modulated by the Kv3 potassium channels.

Disclosed are therapeutic methods for treating a disease or condition characterized by decreased expression or reduced function of an ion channel using an amphotericin B derivative, or an amphotericin B derivative and an ion channel modulator. The methods can be used to treat cystic fibrosis.

Disclosed herein are compounds for treating a condition modulated by calcium channel ion activity and pharmaceutical compositions comprising the compounds, wherein the compounds comprise an azaspirononane core and left- and right-hand substitutions of the azaspirononane core. Also disclosed herein are methods using the compounds to treat a disease or condition relating to aberrant function or activity of a T-type calcium channel.

A novel sodium channel modulator compound and its uses are presented below. The sodium channel modulator has a completely new structure as shown in formula I, and shows excellent in vitro inhibitory effect against Nav1.8. This compound or its pharmacologically acceptable salt can be used to treat sodium channel-related diseases, including diseases such as pain, multiple sclerosis, Charcot-Marie-Tooth disease, incontinence, pathological cough, or arrhythmia.

Disclosed herein are compounds for treating a condition modulated by calcium channel ion activity and pharmaceutical compositions comprising the compounds, wherein the compounds comprise an azaspiroheptane core and left- and right-hand substitutions of the azaspiroheptane core. Also disclosed herein are methods using the compounds to treat a disease or condition relating to aberrant function or activity of a T-type calcium channel.

We provide formulations of ion channel modulators. [Solution] The present invention partially relates to compositions or dosage forms comprising condensed heteroaryl compounds useful for preventing and / or treating diseases or conditions associated with abnormal function of voltage-gated sodium ion channels, such as abnormal delayed / persistent sodium currents. Methods for treating diseases or conditions associated with abnormal function of sodium ion channels, including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, neuromuscular disorders, trigeminal-autonomic headache (TAC), migraines, cranial nerve disorders or polycranial nerve disorders, and cortical spreading depression (CSD), are also provided herein. In another aspect, the present invention provides methods for producing ion channel modulators.

Disclosed herein are compounds for treating a condition modulated by calcium channel ion activity and pharmaceutical compositions comprising the compounds, wherein the compounds comprise a diazaspiroheptane core and left- and right-hand substitutions of the diazaspiroheptane core. Also disclosed herein are methods using the compounds to treat a disease or condition relating to aberrant function or activity of a T-type calcium channel.

Provided, in part, are compounds of Formula I:pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with the activity of sodium channels. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.

The application discloses a use of patchouli oil or patchouli alcohol in preparation of a TRP channel modulator. The patchouli oil or patchouli alcohol has a function of regulating a TRP channel, and particularly has a synergistic effect with a TRPM2 inhibitor in anti-inflammatory effect, and is a promising TRPM2 inhibitor. In addition, the patchouli alcohol or patchouli oil has a function of improving colitis-related injury, and can inhibit expression of IL-1beta, TNF-alpha, IL-6, TRPM2, TRPM6 and TRPM7 genes.

The invention discloses a DRM channel modulator based on a CORDIC algorithm. The DRM channel modulator comprises an FPGA module used for realizing logical operation and supporting double-clock domain operation; the memory module is used for caching rate mismatch data between the front-stage encoder and the rear-stage modulator; the clock module is provided with double frequencies, the clock module is used for serving high-speed operation and low-speed signal processing, and the clock module realizes synchronization of two paths of clocks through an MMCM; and the high-speed AD / DA module is used for digital pre-distortion closed-loop correction expansion. Parallel processing of 1024 subcarriers is supported through the assembly line CORDIC, and the single symbol delay is far smaller than the minimum symbol period of the DRM. Due to the one-hot code and check bit design, the bit error rate during signal-to-noise ratio is reduced by two orders of magnitude compared with that of a traditional scheme; iFFT (Inverse Fast Fourier Transform) points can be configured, DRM30 and DRM + modes are supported, and an existing transmitter modulation module can be directly replaced.

The present disclosure provides compounds, compositions, and methods for modulating plasma membrane Cav1.3 calcium channels and treating diseases or disorders (e.g., Parkinson's disease, aldosteronism) with the compounds or compositions thereof. In particular, disclosed herein are modified pyrimidine-2,4,6-triones and modified dihydropyridines that have elevated potency and selectivity for Cav1.3 Ca2+ channels, and compositions and formulations thereof.